Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Income from Continuing Operations (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Income from Continuing Operations for 12 consecutive years, with 4249000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 13.81% year-over-year to 4249000.0, compared with a TTM value of 18242000.0 through Sep 2025, up 0.91%, and an annual FY2024 reading of 19985000.0, up 4.1% over the prior year.
  • Income from Continuing Operations was 4249000.0 for Q3 2025 at Lisata Therapeutics, up from 4659000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3035000.0 in Q4 2023 and bottomed at 6187000.0 in Q1 2023.
  • Average Income from Continuing Operations over 3 years is 4738818.18, with a median of 4724000.0 recorded in 2025.
  • The sharpest move saw Income from Continuing Operations tumbled 51.89% in 2024, then grew 13.81% in 2025.
  • Year by year, Income from Continuing Operations stood at 3035000.0 in 2023, then crashed by 51.89% to 4610000.0 in 2024, then increased by 7.83% to 4249000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for LSTA at 4249000.0 in Q3 2025, 4659000.0 in Q2 2025, and 4724000.0 in Q1 2025.